鼻咽癌患者中血清has-miR-19b的特异性表达及其分子通路初探

Specific expression of has-miR-19b in nasopharyngeal carcinoma and its related molecular pathway

目的:比较血清has-miR-19b在鼻咽癌患者与非癌人群以及鼻咽癌患者放化疗前后的表达差异,探讨其作为鼻咽癌临床诊断潜在分子标记物的意义;同时对has-miR-19b的靶基因SOCS1进行检测,为以后鼻咽癌的分子靶向治疗提供依据。方法:收集鼻咽癌患者、鼻咽癌患者放化疗后、非癌人群血清各30例,通过荧光定量PCR(RT-PCR)技术检测血清has-miR-19b的表达情况,同时通过免疫组化技术检测SOCS1在鼻咽癌患者与非癌人群鼻咽部组织蜡块中的表达情况。结果:(1)与非癌人群相比,血清has-miR-19b在鼻咽癌患者中有明显增高的趋势(P<0.05),鼻咽癌患者放化疗前后,has-miR-19b表达差异无统计学意义。(2)SOCS1在30例非癌人群鼻咽部组织中,有25例呈阳性表达,而在鼻咽癌组织中均呈阴性表达。has-miR-19b与SOCS1存在相关性(r=-0.573,P<0.05)。结论:(1)血清has-miR-19b可能作为鼻咽癌临床诊断的潜在分子标记物。(2)has-miR-19b可能通过调节靶基因SOCS1来调控鼻咽癌的发生。

Objective To compare the differences in serum has-miR-19b expression between patients with nasopharyngeal carcinoma （NPC） and people without tumors and in that between the baselines and postehemoradiotherapy in NPC patients, to explore the significance of has-miR-29c as a clinical diagnostic biomarker for NPC, and to a reference for targeted molecular therapy for NPC by detecting the target gene SOCS1 of has- miR-19b. Methods Serum samples were separately collected from 30 NPC patients, 30 patients undergoing chemoradiotherapy, and 30 people without tumors. Expression of has-miR-19b and protein of SOCS1 were detected by semi-quantitative RT-PCR and immunohistochemistry. Results As compared with people without tumors, serum has-miR-19b levels were increased dramatically in NPC patients （P 〈 0.05）, while there was no obvious difference in the baselines and post-chemoradiotherapy. SOCS1 was positively expressed in 25 of 30 people without tumors but did not expressed in all the 30 NPC patients, has-miR-19b was correlated with SOCSI （r = -0.573, P 〈 0.05）. Conclusions has-miR-19b can be used as a potential molecular marker in the diagnosis of NPC. It may control the occurrence of NPC by regulating the target gene SOCS1.